Positive Results from Disc Medicine's Bitopertin Study in Patients with EPP
Monday, 1 April 2024, 12:52
Disc Medicine Achieves Success in Mid-Stage Study
The mid-stage study of bitopertin by Disc Medicine has yielded promising results for patients with EPP. Significant reductions in protoporphyrin IX levels were observed, demonstrating the drug's efficacy in treating the condition.
Key Highlights:
- Positive outcomes from bitopertin study
- Statistically significant reductions in protoporphyrin IX
- Meeting the primary goal of the study
This success marks a significant milestone in the development of new treatments for EPP patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.